• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
CONCLUSIONS: AF/AFL is a significant risk factor for stroke, HF, and mortality. Additional risk factors for these outcomes were generally similar for participants with and without baseline or incident AF/AFL. PMID: 30126559 [PubMed - in process]
Source: Journal of the National Medical Association - August 22, 2018 Category: General Medicine Tags: J Natl Med Assoc Source Type: research

Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT
Objective:Epidemiologically, there is a strong relationship between BMI and blood pressure (BP) levels. We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m2; normal weight (BMI 30)]. Methods:In a randomized, double-blind, practice-based Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, 33 357 hypertensive participants, aged at least 55 years, were followed...
Source: Journal of Hypertension - June 6, 2014 Category: Cardiology Tags: ORIGINAL PAPERS: Obesity Source Type: research

Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex Clinical Trial - ALLHAT
To determine whether an angiotensin-converting enzyme inhibitor (lisinopril) or calcium channel blocker (amlodipine) is superior to a diuretic (chlorthalidone) in reducing cardiovascular disease incidence in sex subgroups, we carried out a prespecified subgroup analysis of 15 638 women and 17 719 men in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Total follow-up (active treatment + passive surveillance using national administrative databases to ascertain deaths and hospitalizations) was 8 to 13 years. The primary outcome was fatal coronary heart disease or nonfatal myocardial i...
Source: Hypertension - April 17, 2013 Category: Cardiology Authors: Oparil, S., Davis, B. R., Cushman, W. C., Ford, C. E., Furberg, C. D., Habib, G. B., Haywood, L. J., Margolis, K., Probstfield, J. L., Whelton, P. K., Wright, J. T., for the ALLHAT Collaborative Research Group Tags: Primary prevention, Secondary prevention, Clinical Studies Clinical Trial - ALLHAT Source Type: research